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Abstract 
Background 
Ecuador is in malaria pre-elimination phase, with a reduction of more than 99% in the 
incidence of confirmed cases that were reported between 2000 and 2013. In Ecuador 
malaria is caused by Plasmodium vivax and P. falciparum protozoan species. Invasion of 
erythrocytes is essential for the development of the disease in the human host. P. vivax 
requires a specific interaction with antigens Fy
a
 or Fy
b
, corresponding to the Duffy 
receptor in the red blood cells. The Duffy polymorphism affects P. vivax ability to invade 
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erythrocytes. This study aimed to determine the malaria prevalence and the composition of 
Duffy polymorphisms of the population of four communities of San Lorenzo county in 
northwest Ecuador. 
Methodology/Findings 
Blood samples from a total of 797 individuals were collected in El Pedregal, Ricaurte, 
La Boca and El Guadual communities in northwest Ecuador. Plasmodium detection and 
Duffy allele genotyping were performed by qPCR. The malaria prevalence in 2015 was 
compared to previously report in 2013. We found 4.5% malaria prevalence in 2015 that 
was lower than the reported prevalence for 2013. Most of positive infections (77.8%) were 
caused by P. vivax and 97.3% were asymptomatic. San Lorenzo population had 70.4% of 
Duffy positive phenotypes prevalence and 29.6% of Duffy negative phenotype prevalence. 
Six cases of P. vivax infected individuals with a Duffy negative genotype were found.  
Conclusions 
The results show a high prevalence of asymptomatic malaria in Northwest Ecuador 
being P. vivax the most frequent species detected. Moreover, the Duffy blood group system 
in the study sites is highly heterogeneous, with three alleles FY*A, FY
*
B and FY
*
B
ES
 
present. In addition, we report for the first time in the pacific region of South America 
Duffy negative individuals infected with P. vivax. Taken together, the results show that the 
situation of malaria in northwest Ecuador is far from understood. 
Author Summary 
Malaria is a disease caused by Plasmodium protozoans and transmitted by Anopheles 
mosquitoes, that kills almost 584000 persons a year. Ecuador is a country of Northwest 
South America that has been very successful in controlling malaria and is now in pre-
elimination phase. Nevertheless, several cases and outbreaks are still being reported. 
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Malaria cases are restricted to the Coast and Amazon regions of Ecuador, and is caused by 
two species, P. vivax and P. falciparum. Recent reports show a high asymptomatic 
prevalence than sustain transmission preventing malaria control and elimination. The 
genetic composition of the human population is an important factor that can influence the 
transmission process of malaria disease. In particular, the Duffy blood group 
polymorphisms affect P. vivax infection rates. The results of this study showed a high 
prevalence of asymptomatic malaria caused by P. falciparum and P. vivax with low 
parasitemias. Also it was found that in the study region, P. vivax is able to invade the red 
blood cells in a Duffy independent way.  
Introduction 
Malaria is a disease of tropical and subtropical countries caused by Plasmodium 
protozoans. Five species are recognized as natural malaria parasites of humans (P. 
malariae, P. ovale, P. falciparum, P. vivax and P. knowlesi). Due to its biology, P. 
falciparum is the specie that causes most mortality and P. vivax is the most widely 
distributed human malaria parasite in the world outside sub-Saharan regions of Africa [1].  
Several studies have shown that in endemic malaria areas asymptomatic and 
submicroscopic infections are common [2-4]. In areas pursuing malaria elimination it is 
necessary to monitor all Plasmodium infections that could contribute to maintain 
transmission and persistence of malaria within endemic regions (including submicroscopic 
and asymptomatic infections that generally remain undetected and untreated) [3,4].  
Ecuador is in malaria pre-elimination phase with a reduction of more than 99% in the 
incidence of confirmed malaria cases reported between 2000 and 2013. In 2000, 104600 
cases were reported; in 2005, 17050 cases; in 2010, 1888 cases; in 2011, 1233 cases; in 
2012, 558 cases; in 2013, 378 cases and in 2014, 243 cases [1,5,6]. In Ecuador the 
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presence of malaria is restricted to the Coast and Amazon regions, and is caused by two 
species of Plasmodium: P. vivax (that accounted 86% of the registered cases in 2012 and 
83% in 2014) and P. falciparum (that caused 14% of the cases in 2012 and 17% in 2014) 
[1,7].  
Invasion of erythrocytes is essential for the completion of the Plasmodium life cycle and 
development of malaria. Plasmodium invades and multiplies within host erythrocytes 
during the blood-stages of its life cycle [8]. The invasion process is complex and involves 
multiple steps. In particular, a specific binding and junction formation between the parasite 
ligands and erythrocyte receptors is essential for Plasmodium invasion of erythrocytes. 
This process varies greatly among different species of Plasmodium: P. falciparum uses 
multiple invasion pathways and multiple receptors while P. vivax requires interaction of 
the Duffy Binding Protein (DBP) with the antigens Fy
a
 or Fy
b
, from a single receptor 
called Duffy or DARC (Duffy antigen receptor for chemokines) [9-12]. Therefore, Duffy 
polymorphisms are implied in the susceptibility or resistance of human populations to P. 
vivax [10,11,13,14]. 
The Duffy polymorphisms are the result of the different combinations of the three main 
alleles of the Fy gene: FY*A, FY*B and FY*B
ES 
(ES: stands for erythrocyte silent). FY*A 
and FY*B alleles express the antigens Fy
a
 or Fy
b
 respectively; the SNP that differentiates 
this alleles is a single nucleotide substitution at position 125 (G>A) [15,16]. The FY*A, 
FY*B alleles expression is codominant and results in four possible phenotypes: Fy(a+b-), 
Fy(a-b+), Fy(a+b+) and Fy(a-b-) [16,17]. The first three correspond to Duffy positive 
phenotypes. The Fy(a+b-) phenotype predominates in southeast Asia and in many 
American populations, the Fy(a-b+) phenotype predominates in European populations, the 
Fy(a+b+) predominates in North Africa and some American populations [11]. 
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The negative phenotype Fy(a-b-) is associated with a single nucleotide mutation in the 
GATA-box promoter region of the FY gene, (C>T) at position -33, which disrupts a 
binding site for the GATA-1 erythroid transcription factor. In fact, it abolishes the 
receptor´s expression [11,13,18]. The absence of the Duffy receptor confers resistance to 
P. vivax infection [12-14,16,18,19]. This phenotype predominates in some populations of 
Africa where malaria is endemic, but P. vivax reported cases are low or non-existent 
[11,17,19]. Several new reports show infection of P. vivax in Duffy negative individuals in 
Kenya [20], Ethiopia [21], Madagascar [22], Mauritania [23], Brazilian Amazon [24,25], 
Angola and Equatorial Guinea [26], suggesting that P. vivax may also have redundancy in 
invasion pathways resulting from a recent evolution of the parasite. 
The Duffy blood group distribution and the incidence of malaria in Rio Cayapas region 
(Esmeraldas province) northwest Ecuador was studied in 1985. The population was 
composed of two distinct racial groups: Blacks (African descent) and Chachi (indigenous 
population). The results showed an incidence twice higher of P. vivax infection in the 
Chachi group than what was found in the Black population, this last one with 76% 
prevalence of Duffy negative phenotype [27]. The present study aimed to determine the 
malaria prevalence and Duffy genotypes in four malaria-endemic locations in San Lorenzo 
county of Esmeraldas province using quantitative PCR (qPCR) and identify a possible 
association between the two in order to improve our understanding of the malaria situation 
in the area. 
Methods 
Ethics statement and surveys 
The ethical and methodological aspects of this study were carried out in accordance 
with international ethics procedures for the use of human subjects in research and were 
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approved by Pontificia Universidad Católica del Ecuador Ethics Committee. Each 
participant was informed of the aims of the study and the volunteers signed a written 
informed consent.  
A symptoms survey was answered by the participants. The ethnicity data was obtained 
through a knowledge, attitude and practices (KAPs) survey. 
Study area and population 
The samples for this study were collected in February 2015 in a cross-sectional study 
conducted in Ecuadorian malaria endemic areas: four communities (El Pedregal, Ricaurte, 
La Boca and El Guadual) were selected in Esmeraldas province, San Lorenzo county in 
northwest Ecuador. El Pedregal is located in San Lorenzo city and has 270 inhabitants. 
Ricaurte is located about 15 km southeast from San Lorenzo city, with a population of 
1381 inhabitants. La Boca is located 7 km southwest of Ricaurte with approximately 580 
inhabitants. El Guadual is located about 40 km southeast from La Boca and it has a 
population of approximately 280 inhabitants (Fig. 1). El Pedregal, Ricaurte and La Boca 
are lowland communities located at 30 masl, 41 masl and 30 masl respectively, with 
predominant Afro-descendants population. While El Guadual is a community located at 
649 masl with predominant Mestizo population. 
Blood samples and DNA extraction 
The sample size was calculated for each community with a confidence level of 95%, 
using OpenEpi v.3.03a software. In total 797 samples were examined (El Pedregal, n=151, 
Ricaurte, n=281, La Boca n= 226 and El Guadual n= 139). Blood samples were collected 
on filter paper (Whatman 3MM chromatography paper) and DNA was extracted from dried 
blood spots using the PureLink Genomic DNA mini kit (Invitrogen).  
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Parasite detection and comparison with malaria prevalence in 2013 
The molecular diagnosis of malaria infection and identification of Plasmodium species 
was performed using real time PCR, Applied Biosystems 7500 v.2.0.5 analytical PCR 
system. The amplification was done using primers that target the cytochrome oxidase 1 
(CO1) of P. vivax or P. falciparum, following the protocol of CLAIM (Centro 
Latinoamericano de Investigación en Malaria). The qPCR reactions were carried out in 96-
well 0.1 ml thin-wall optical PCR plates with optical adhesive film sealing tapes (Applied 
Biosystems). The 10 µl reaction mixture contained 2 µl of genomic DNA, 5 µl of TaqMan 
Universal PCR Master Mix (Applied Biosystems), 10 µM of each parasite species-specific 
primer, 10 µM of each fluorescence labelled probes to hybridize differentially to P. vivax 
or P. falciparum enabling species identification. The primer and probe sequences are listed 
in Table 1. The PCR amplification profile used was previously described with minor 
modifications [28-30], and consisted of an initial denaturation at 95°C for 10 min, 45 
cycles of 95°C for 15s and 60° for 1 min. Standard P. falciparum and P. vivax DNA 
positive and negative controls were used. The parasitemia quantification was performed 
using a parasite-specific standard curve obtained by diluting controls. 
Malaria prevalence, asymptomatic infections and Plasmodium species prevalence were 
compared with the results of a previous study conducted in 2013 in the same communities 
[31]. The formula “∆%= 
𝑑𝑎𝑡𝑎 2015−𝑑𝑎𝑡𝑎 2013
𝑑𝑎𝑡𝑎 2013
” was used to calculate the variation percentage 
of each variable in two years.  
Duffy blood group genotyping 
Forty percent of samples of each community were randomly selected (all the samples 
infected with P. vivax and P. falciparum were included in the analysis). The Duffy allele 
genotyping was performed by qPCR as described by Sousa et al. [32]. A 10 µl PCR 
mixture was performed using 2 µl of genomic DNA, 5 µl of SYBR Green PCR Master 
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Mix (Applied Biosystems), four different combinations of primer pairs (adapted from 
[32]). The primer sequences are listed in Table 1. In each plate, positive controls were 
included for genotypes FY*A/FY*A, FY*A/FY*B, FY*A/FY*B
ES
, and FY*B
ES
/FY*B
ES
. 
The amplification and fluorescence detection were performed using an Applied Biosystems 
7500 v.2.0.5 analytical PCR system under the following conditions: initial denaturation at 
95°C for 10 min, then 35 cycles of 95°C for 15 s and 60°C for 1 min.  
Comparison of Duffy phenotypes/genotypes in lowland communities and El Guadual 
and among P. vivax-infected and non P. vivax-infected individuals 
The data obtained of phenotypes, genotypes and allelic prevalences of Duffy blood 
group were compared between lowland communities (El Pedregal, Ricaurte and La Boca) 
and El Guadual (located in a higher area of San Lorenzo county). 
The data obtained of phenotypes, genotypes and allelic prevalences of Duffy blood 
group were compared among P. vivax infected, P. falciparum infected and non-infected 
individuals. P. falciparum infected and non-infected individuals were analyzed together as 
a control group because P. falciparum does not use Duffy antigens to invade erythrocytes. 
Statistical analysis 
SPSS 18 was used for statistical analysis of the data. Chi-square test (χ2) was used to 
compare the malaria prevalence, asymptomatic infections and Plasmodium species 
prevalence between 2013 and 2015. Chi-square test (χ2) and Fisher´s exact test were used 
to compare the proportions of Duffy phenotypes, genotypes and alleles among 
communities (lowland communities and El Guadual) and among the infections (P. vivax-
infected and non P. vivax-infected individuals). 
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Results 
Ethnic composition of the study communities  
El Pedregal, Ricaurte and La Boca are predominantly Afro-Ecuadorian communities: At 
the community of El Pedregal, 80% of respondents identified themselves as Afro-
Ecuadorians, 12.5% as Mestizo and 7.5% as White-Caucasian. At Ricaurte and La Boca 
more than 90% respondents identified themselves as Afro-Ecuadorians and the remaining 
as Mestizos. At El Guadual 67% of the surveyed identified themselves as Mestizos and the 
remaining as Afro-Ecuadorians (Fig. 2).  
Parasite Detection 
The overall malaria prevalence by qPCR in the four studied communities of San 
Lorenzo county was 4.5% (36/797). The prevalence of infection was much higher in El 
Guadual (10.8%), followed by La Boca (4.0%), Ricaurte (2.8%) and El Pedregal (2.6%) 
(Table 2). The two main species of Plasmodium were identified. P. falciparum showing the 
lowest infection rates (0.7% in El Pedregal and Ricaurte, 0.9% in La Boca and 2.2% in El 
Guadual) and P. vivax with the highest infection rates in all communities. P. vivax was 
detected in 28 individuals, 3 from El Pedregal (2%), 6 from Ricaurte (2.1%), 7 from La 
Boca (3.1%) and 12 from El Guadual (8.6%) (Fig. 3A). The overall parasite distribution 
was 77.8% for P. vivax and 22.2% for P. falciparum (Fig. 3B). No mixed infections were 
detected. 
The mean parasitemia (parasites/µl) determined by qPCR in El Pedregal was 2.25 (1-6 
parasites/µl), in Ricaurte it was 23.88 (1-144 parasites/µl), in La Boca it was 7.78 (1-23 
parasites/µl) and in El Guadual it was 74.67 (1-590 parasites/µl) (Fig. 3C). Among the 
positive cases only 1 presented symptoms with 10 parasites/µl of parasitemia, resulting in 
97% of asymptomatic infections (Fig. 3D). The prevalence of malaria infections in the 
blood samples is presented in Table 2. 
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Table 3 shows a comparison with a study conducted in 2013 in the same communities 
[31]. We observed 39.2% decrease of malaria prevalence in the study area (7.4% in 2013 
to 4.5% in 2015), which was significant (p=0.013). Nevertheless in Ricaurte and El 
Guadual communities the malaria prevalence increased in 64.7% and 96.4% respectively, 
even though the increase was not significant (p=0.299 and p=0.150) (Fig. 4A). A reduction 
of P. vivax prevalence (50%) and an increase of P. falciparum prevalence (100%) were 
observed (Fig. 4B), but only the reduction of P. vivax prevalence was significant 
(p=0.002). The asymptomatic infection percentage was similar in 2013 and 2015 (98% and 
97%, respectively).   
Duffy blood group genotyping 
The data shows 70.4% of Duffy positive phenotypes. Out of these, the Fy(a+b-) was the 
predominant phenotype with a 57.6% prevalence (FY*A/FY*B
ES
 was the most frequent 
genotype, followed by FY*A/FY*A). The percentages for Fy(a-b+) and Fy(a+b+) 
phenotypes were low (8.5% and 4.4%, respectively). The negative Duffy phenotype Fy(a-
b-) (with genotype FY*B
ES
/FY*B
ES
) showed a 29.6% prevalence. The lowest allelic 
frequency was 0.079 for the FY*B allele whereas FY*A and FY*B
ES
 alleles had similar 
frequencies (0.436 and 0.486, respectively). The phenotypic, genotypic and allelic 
frequencies of the Duffy blood group in the 319 analyzed samples are summarized in Table 
4. Representative graphs of melting curves for each genotype are presented in Figure 5. 
The Duffy positive phenotypes were the most common in the four communities of San 
Lorenzo (Fig. 6A), with a significant difference (p=0.000) when comparing the lowland 
communities and El Guadual. We observed an association between the Duffy positive 
phenotype with El Guadual (91.1%) and an association between the Duffy negative 
phenotype and lowland communities (34%) (Table 5).  
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The genotype distribution varied among the study sites. In El Pedregal the most 
common genotype was FY*A/FY*A with 33.3% and the lowest was FY*B/FY*B with 
3.3%. In Ricaurte the most common genotype was FY*B
ES
/FY*B
ES
 with 39% and the 
lowest FY*A/FY*B with 0.9%. In La Boca the most common genotype was FY*A/FY*B
ES
 
with 48.9% and the lowest FY*B/FY*B
ES
 with 2.2%. In El Guadual the most common 
genotype was FY*A/FY*A with 53.6% and the lowest FY*B/FY*B
ES 
with 3.6%, while the 
FY*B/FY*B genotype was absent (Fig. 6B).  
When comparing the genotypes between lowland communities and El Guadual we 
observed significant differences with FY*A/FY*A, FY*A/FY*B and FY*B
ES
/FY*B
ES
 
genotypes (p=0.000, p=0.022 and p=0.000, respectively). We observed an association 
between lowland communities with the FY*B
ES
/FY*B
ES
 genotype, and association of El 
Guadual with FY*A/FY*A and FY*A/FY*B genotypes (Table 5). Additionally, when we 
compared the allele prevalence, an association between FY*B
ES
 allele with lowland 
communities and FY*A allele with El Guadual were found (p=0.000) (Table 5). 
Duffy blood group genotypes in P. vivax-infected and non P. vivax-infected 
individuals 
Table 6 shows a comparison of the results of inferred Duffy phenotypes among P. vivax 
infected individuals and a control group (P. falciparum infected and non-infected 
individuals). In the control group 69.7% were Duffy positives and 30.3% were Duffy 
negative. Among P. vivax positive by qPCR, 78.6% were Duffy positives and 21.4% were 
Duffy negative (six individuals). Of these six Duffy negative individuals one was from El 
Pedregal, four from Ricaurte and one from La Boca. The risk of Duffy negatives to 
experience a P. vivax blood stage infection was lower but not significantly different from 
that of Duffy positives (p=0.224). 
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No significant differences were observed when comparing the genotypic prevalence of 
the Duffy blood group among P. vivax infected and control group in El Pedregal, Ricaurte 
and La Boca communities. However, in El Guadual the FY*A/FY*B
ES 
genotype showed 
association with the resistance to P. vivax infection (p=0.027). When all samples were 
analyzed together, we observed an association between the FY*A/FY*A genotype and the 
risk of P. vivax infection (p=0.025) (Table 7). 
With respect to the FY alleles frequency, there was a significant difference between P. 
vivax infected and the control group only for FY*B
ES
 allele (p=0.024 and p=0.033 in El 
Guadual and total samples, respectively). There was a 0.498 FY*B
ES
 allele frequency in the 
control group and 0.357 FY*B
ES
 allele frequency in P. vivax infected individuals, showing 
an association between FY*B
ES 
allele and the resistance to P. vivax infection (Table 8).  
Discussion 
The prevalence of Plasmodium and Duffy blood group phenotypes and genotypes was 
studied in four communities of San Lorenzo, Esmeraldas province, an area of malaria 
transmission in the north Ecuadorian Coast, in order to analyze the relation between P. 
vivax infection and Duffy blood group polymorphisms.  
This study shows a 4.5% malaria prevalence out of which 97% were asymptomatic. P. 
vivax was the most common species detected (3.5%) and only 1% prevalence of P. 
falciparum was identified (Fig. 4). When comparing these results to the study conducted in 
the same communities by Sáenz et al. in 2013 [31], we observed a significant decrease of 
39.2% in malaria prevalence (7.4% in 2013, 4.5% in 2015). Nevertheless, Ricaurte and El 
Guadual showed an increase in malaria prevalence which was not significant (Fig. 5A). In 
2013, 94% of Plasmodium infections were caused by P. vivax and 6% were caused by P. 
falciparum; while in 2015, 78% of Plasmodium infections were caused by P. vivax and 
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22% were caused by P. falciparum. The data show a significant reduction of P. vivax 
prevalence and no significant increase of P. falciparum prevalence in the study site 
(p=0.002 and p=0.194, respectively) (Fig. 5B).  
The positive cases in the present study have low parasitemias (1-590 parasites/µl; mean: 
27.22 parasites/µl) according to the parasitemia classification described by Bamaga et al. 
in 2014 [33]. These results are consistent with previous studies in malaria endemic areas 
where P. vivax is the predominant species and the prevalence of sub-microscopic 
infections varies between 3 to 20% [2,30]. In South America a high prevalence of sub-
microscopic and asymptomatic infections were reported (between 59% and 98%), in 
countries such as Colombia [30], Ecuador [31], Perú [34], Venezuela and Brazil [35,36].   
The asymptomatic cases can act as reservoirs of parasites and asymptomatic carriers can 
transmit the parasite to other individuals preventing malaria control and elimination 
[3,4,30]. The results obtained in this study are relevant because they show high 
asymptomatic and sub-microscopic malaria prevalence in the northwest of the country. In 
particular, in El Guadual, the community with higher prevalence, there was a P. falciparum 
outbreak (19 clinical cases) [6] shortly after sampling, that could have been originated by 
asymptomatic infections identified in this study. The molecular diagnosis is important to 
identify low parasitemias, frequently asymptomatic, which are not detected by standard 
methods but can be transmitted and cause clinical outbreaks [30,37]. Consequently, 
asymptomatic infections should be taken in account in elimination policies of the disease 
in the region [37,38]. 
Although the Duffy blood group distribution and the incidence of malaria in Rio 
Cayapas in Esmeraldas were studied in 1985, little is known on the frequency of red blood 
cell polymorphism that confers either partial or complete resistance against malaria in 
Ecuador. In the previous study, 62.5% of Duffy positive and 37.5% of Duffy negative 
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phenotypes were found in lowland communities, and the incidence of P. vivax was twice 
high in the Duffy positive individuals than in the Duffy negative subjects [27]. El Pedregal, 
Ricaurte and La Boca are lowland communities of San Lorenzo county and the percentages 
of Duffy phenotypes are similar to what was found by Guderian et al. in Rio Cayapas, with 
67% of Duffy positive and 33% of Duffy negative phenotype. The variation found is 
possibly due to population changes that have occurred over time, such as new population 
mixtures and migrations. On the other hand, El Guadual community is located in a higher 
area of San Lorenzo county (649 masl), and 91% of Duffy positives and 9% of Duffy 
negatives phenotypes were found. These results can be explained because of the ethnic 
composition of this community, with predominant Mestizo population (66,7%) in 
opposition to Afro-descendants in the lowland communities (El Pedregal, Ricaurte and La 
Boca). 
The Duffy blood group system in San Lorenzo communities is polymorphic with three 
alleles FY*A, FY*B and FY*B
ES
 presented; the data obtained demonstrates high 
heterogeneity of these alleles in the population. When analyzing the allele frequencies, the 
most common allele was FY*B
ES 
(0.486), although there was a higher prevalence of Duffy 
positive phenotypes, because of the great amount of heterozygous genotype 
(FY*A/FY*B
ES
). As it has been previously reported [27], in this study we found an 
association between the Duffy positive phenotype with Mestizo population and an 
association between Duffy negatives and Afro-Ecuadorians population (p=0.000). Also we 
observed an association between lowland communities with FY*B
ES
/FY*B
ES
 genotype and 
FY*B
ES
 allele, and an association of El Guadual with FY*A/FY*A and FY*A/FY*B 
genotypes, and the FY*A allele (p-values in Table 5). These results are consistent with 
previous reports that show a relationship between the ethnic composition and the different 
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Duffy phenotypes, mainly African descendents with Duffy negative phenotype 
[13,16,18,19,27]. 
When comparing the phenotype prevalence between P. vivax infected individuals and 
the control group (P. falciparum infected and non-infected individuals) no significant 
differences were observed, emphasizing the importance of the evaluation of Duffy 
polymorphism in malaria endemic areas. Although it is know that Duffy negative genotype 
confers resistance to P. vivax blood-stage infection, in the current study, six P. vivax 
infected individuals that presented a Duffy negative genotype were reported: one in El 
Pedregal, four in Ricaurte and one in La Boca. Therefore, the risk of Duffy negatives to 
experience a P. vivax blood stage infection was lower but not significantly different to that 
of Duffy positives (p=0.224). Similar results were found in other studies with recent 
reports of different parts of malaria endemic area, such as Kenya [20], Ethiopia [21], 
Madagascar [22], Mauritania [23] and the Brazilian Amazon [24,25]. Nevertheless, this is 
the first report of Duffy negative individuals infected with P. vivax in the Pacific region of 
South America. 
The reason by which Duffy negative individuals could be infected by P. vivax has not 
been determined. Several factors may be involved, mainly the species biology because of 
its extraordinary capacity to adapt [21,26]. In regions where the Duffy positive phenotype 
is most common, people could be a reservoir of P. vivax giving the opportunity to infect 
hepatocytes of Duffy negative people and the capacity to develop new forms to invade 
erythrocytes [21,22,24,26]. Another factor to take into account is that P. vivax could be 
able to infect human red cells through a Duffy independent mechanism; using more than a 
pathway of invasion, possibly by an alternative receptor [26]. In addition new P. vivax 
strains that do not depend of the Duffy antigen for invasion could be appearing [21].  
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We did not find significant differences in Duffy genotypes among P. vivax infected and 
control groups in El Pedregal, Ricaurte and La Boca communities. These results are 
inconsistent with previews reports than show a relationship between the genotypes and the 
susceptibility of P. vivax infection [10,11,13,14], but similar results were found in Anajás-
Brazil, where Carvalho et al. did not find different frequencies between genotypes that had 
a higher prevalence of Duffy positive people [24]. However, in El Guadual the 
FY*A/FY*B
ES
 genotype showed an association with the resistance to P. vivax infection 
(p=0.027). When the total samples were analyzed together we observed an association 
between the FY*A/FY*A genotype and the P. vivax risk (p=0.025). This result is 
inconsistent with King et al. [11] who found that the Fy
a
 antigen is associated with 
protection because it reduces the risk of P. vivax in humans compared with Fy
b
, in an in-
vitro experiment. This apparent discrepancy may be due to the genetic composition of El 
Guadual community where the majority of the people have a FY*A/FY*A genotype. Also 
there are other possible risk factors that influence a high prevalence in this community 
such as the knowledge, attitudes and practices towards malaria this community [38] or 
possibly a greater presence of the vector.   
The frequency of FY*B
ES 
was greater in the control group than in P. vivax infected 
individuals when the alleles were analyzed (p=0.024 in El Guadual and p=0.033 globally), 
suggesting that as presented elsewhere there is an association with the resistance to be 
infected by P. vivax and this allele. This is consistent with reports than manifest the 
presence of the FY*B
ES
 allele may be a selective advantage because reducing the rate of 
infection by P. vivax [11-14,16,30,31] and show that the presence of the FY*B
ES
 allele 
results in a 50% reduction in the Duffy protein expression on the erythrocyte surface when 
it is present in a heterozygote form [39,40]. 
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In conclusion, the results obtained in this study are highly relevant. First, they confirm 
that the presence of sub-microscopic and asymptomatic malaria infections in Ecuador. 
Therefore, it is necessary to employ more sensitive techniques such as qPCR for correct 
diagnosis and treatment to eliminate malaria in endemic regions, together with policies, 
plans and programs that the Ministry of Public Health needs to implement.   
Second, these findings show for the first time in the pacific of South America the ability 
of P. vivax to infect Duffy negative individuals. Although we do not know which are the 
circumstances that lead to this process, it is important to explore the different mechanisms 
of P. vivax infection and its ability to adapt, because it can result in one of the causes that 
difficult the elimination of this parasite.  
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Figures 
 
Figure 1. Study sites. Map of the four study sites in San Lorenzo county, Esmeraldas 
province in northwest Ecuador.  
  
24 
 
El
 P
ed
re
ga
l
Ri
ca
ur
te
La
 B
oc
a
El
 G
ua
du
al
0
10
20
30
40
50
60
70
80
90
100
Afro-Ecuadorians
White-Caucasian
Mestizo
Community
P
e
rc
e
n
ta
g
e
 (
%
)
 
Figure 2. Ethnic composition of the study communities. El Pedregal, Ricaurte and La 
Boca communities are predominantly Afro-Ecuadorian and El Guadual community is 
predominantly Mestizo. A small portion of the population in El Pedregal community 
identified themselves as White-Caucasian (7.5%).   
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D.  
Figure 3. Malaria prevalence in the four study communities of San Lorenzo by 
qPCR. A) Prevalence of P. vivax and P. falciparum in the study areas. El Guadual 
had a higher percentage of cases of both parasites; B) Distribution of Plasmodium 
species as a percentage of positives cases in the communities. P. vivax was the most 
prevalent parasite in all communities; C) Parasitemia levels in the study areas, the 
mean parasitemia was higher in El Guadual (74.67 parasites/µl), followed by 
Ricaurte (23.88 parasites/µl); D) Malaria prevalence according symptoms. There 
was a 97% prevalence of asymptomatic malaria infections.  
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A. 
 
B.
Figure 4. Comparison of malaria prevalence in the study sites in 2013 and 2015. A) 
Malaria prevalence in 2013 and 2015. There is an 80% and 61.2% prevalence decrease in 
El Pedregal and La Boca respectively. There is a 64.7% and 96.4% increase of prevalence 
in Ricaurte and El Guadual respectively; B) Distribution of positive cases by species in the 
study sites. An increase of P. falciparum prevalence (100%) in all communities and an 
increase of 96.4% in prevalence cases in the highlands region (El Guadual) were observed. 
The circle size is proportional to the prevalence (Map: CLAIM, 2015). 
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Figure 5. Representative curves of Duffy genotyping by real-time PCR. The graphics 
show the melting curves obtained using four multiplex reactions. The results were 
interpreted using the melting temperature of amplified alleles. FY*A and FY*B alleles have 
a melting temperature of 77-78°C. The wild type and mutation at position -33 in the GATA 
box have a melting temperature of 86-88°C. A) Genotype FY*A/FY*B
ES
. Four melting 
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curves were observed: allele A, allele B, wild type and mutation at position -33; B) 
Genotype FY*B/FY*B
ES
. Three melting curves were observed: allele B, wild type and 
mutation at position -33; C) Genotype FY*A/FY*B. Three melting curves were observed: 
allele A, allele B and wild type at position -33; D) Genotype FY*A/FY*A. Two melting 
curves were observed: allele A and wild type at position -33; E) Genotype FY*B/FY*B. 
Two melting curves were observed: allele B and wild type at position -33; F) Genotype 
FY*B
ES
/FY*B
ES
. Two melting curves were observed: allele B and mutation at position -33. 
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Figure 6. Prevalences of Duffy blood group phenotypes and genotypes. A) Pie graphs 
showing the distribution of prevalences of Duffy positive and Duffy negative phenotypes 
in the study communities. We observed an association between the Duffy positive 
phenotype with El Guadual (91.1%) and an association between Duffy negative and 
lowland communities (34%) (p=0.000); B) Pie graphs showing distribution of prevalences 
of Duffy genotypes. The Duffy blood group system is highly heterogeneous. Ricaurte and 
La Boca populations had a specific genotypic composition where the predominant 
genotypes were FY*A/FY*B
ES 
and FY*B
ES
/FY*B
ES
, which differ from the other two 
communities where the predominant genotype was FY*A/FY*A. 
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Tables 
Table 1. Primers and probes used in this study. 
Primer/direction Sequence Use 
PfCoxIF/sense 5´-CAA CCA ATT GCT TTT GTT TTA G-3´  Detection of P. falciparum 
PfCoxIR/reverse 5´-ACA GGA GAT AAT GAC ATT AAA GA-3´ Detection of P. falciparum 
PvCoxIF/sense 5´-CAG CAG AAT TTG GAG GAG-3´ Detection of P. vivax 
PvCoxIR/reverse 5´-CTA GCA ATA CCA GAT ACT AAA AG-3´ Detection of P. vivax 
P. falciparum N 
/56-FAM/AAG TCC ATC /ZEN/CAG TTC CAC 
CAC /3IABkFQ/ 
Detection of P. falciparum 
P. vivax N 
/5HEX/ACA ATG ATA /ZEN/ACA TCT ACT GCA 
ACA GGA /3IABkFQ/ 
Detection of P. vivax 
FAB/sense 5´-CCC TCA TTA GTC CTT GGC TCT TTT-3´ 
Identification of wild type at 
position -33 (T) 
FGATA/sense 
5´-CCCGGGCCCGCCG CCC TCA TTA GTC CTT 
GGC TCT TTC-3´ 
Identification of mutation at 
position -33 (C) 
RABGATA/reverse 5´-A GGG GCA TAG GGA TAA GGG ACT-3´ 
Identification of wild type 
and mutation at position -33 
FY/sense 5´-C TCA AGT CAG CTG GAC TTC GAA GAT-3´  
Identification of Fy*A and 
Fy*B alleles 
RYA/reverse 5´-AG CTG CTT CCA GGT TGG CTC-3´ Identification of Fy*A allele 
RYB/reverse 5´-CTG CTT CCA GGT TGG CGT-3´ Identification of Fy*B allele 
 
Table 2. Malaria prevalence by qPCR in the study sites. 
 
Positive cases P. vivax P. falciparum 
Community n % n % n % 
El Pedregal 
(n=151) 
4 2.6 3 2 1 0.7 
Ricaurte 
(n=281) 
8 2.8 6 2.1 2 0.7 
La Boca 
(n=226) 
9 4 7 3.1 2 0.9 
El Guadual 
(n=139) 
15 10.8 12 8.6 3 2.2 
TOTAL 
(N=797) 
36 4.5 28 3.5 8 1 
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Table 3. Comparison of malaria prevalence in the study sites in 2013 and 2015.  
 
2013 2015 
% of increase or 
decrease in 
prevalence 
p-value
a 
Malaria prevalence 7.4% 4.5% Decrease of 39.2% 0.013 
El Pedregal 13.0% 2.6% Decrease of 80% 0.001 
Ricaurte 1.7% 2.8% Increase of 64.7% 0.299 
La Boca 10.3% 4.0% Decrease of 61.2% 0.012 
El Guadual 5.5% 10.8% Increase of 96.4% 0.150 
P. vivax prevalence 7.0% 3.5% Decrease of 50% 0.002 
P. falciparum 
prevalence 
0.5% 1.0% Increase of 100% 0.194 
Asymptomatic 
malaria prevalence 
98% 97% Decrease of 1% 0.676 
a
 P-value was determined by χ2 analysis 
Table 4. Duffy blood group genotypes and phenotypes by real-time multiplex allele-
specific PCR in four communities of San Lorenzo. 
Predicted Phenotype n (%) Genotype Result n (%) Allele frequency 
Duffy positive 
224 (70.4) 
Fy(a+b-) 
183 
(57.55) 
FY*A/FY*A 80 (25.16) 
FY*A 0.436 
FY*A/FY*B
ES
 103 (32.39) 
Fy(a-b+) 27 (8.49) 
FY*B/FY*B 9 (2.83) 
 
FY*B 
 
0.079 
FY*B/FY*B
ES
 18 (5.66) 
Fy(a+b+) 14 (4.40) FY*A/FY*B 14 (4.40) 
    
Duffy 
negative 94 
(29.6) 
Fy(a-b-) 94 (29.56) FY*B
ES
/FY*B
ES
 94 (29.56) FY*B
ES
 0.486 
 
  
34 
 
Table 5. Prevalence of Duffy phenotypes, genotypes and alleles in lowland communities 
and El Guadual. 
  Lowland 
communities
a
 
El Guadual p-value
b
 
Duffy 
phenotype 
(predicted) 
   
Positives 66% 91.1% 0.000 
Negative      34% 8.9% 0.000 
Duffy genotype 
   
FY*A/FY*A 19.1% 53.6% 0.000 
FY*A/FY*B
ES
 34.4% 23.2% 0.070 
FY*B/FY*B 3.4% - 0.171 
FY*B/FY*B
ES
 6.1% 3.6% 0.356 
FY*A/FY*B 3.1% 10.7% 0.022 
FY*B
ES
/FY*B
ES
 34.0% 8.9% 0.000 
Alleles 
   
FY*A 56.1% 87.5% 0.000 
FY*B 12.2% 14.3% 0.406 
FY*B
ES
 74.4% 35.7% 0.000 
a
El Pedregal, Ricaurte and La Boca communities 
b
P-value was determined by χ2 analysis and the Fisher´s exact test.  
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Table 6. Predicted Duffy phenotypes in P. vivax infected and non-vivax infected 
individuals in four communities of San Lorenzo.  
Place 
 
Duffy phenotype 
(predicted)  
P. vivax 
infected          
n (%) 
 
Controls
a
            
n (%)  
p-value
b
 
El Pedregal 
 
Positive 
 
2 (66.7) 
 
40 (70.2) 
 
0.665 
  
 
Fy(a+b-) 
 
2 (66.7) 
 
31 (54.39) 
 
0.576 
  
 
Fy(a-b+) 
 
0 
 
5 (8.77) 
 
0.767 
  
 
Fy(a+b+) 
 
0 
 
4 (7.02) 
 
0.810 
   Negative    Fy(a-b-)   1 (33.3)  17 (29.8)  0.665 
Ricaurte 
 
Positive 
 
2 (33.3) 
 
66 (62.3) 
 
0.163 
  
 
Fy(a+b-) 
 
1 (16.7) 
 
51 (48.11) 
 
0.140 
  
 
Fy(a-b+) 
 
1 (16.7) 
 
14 (13.21) 
 
0.587 
  
 
Fy(a+b+) 
 
0 
 
1 (0.94) 
 
0.946 
   Negative    Fy(a-b-)   4 (66.7)  40 (37.7)  0.163 
La Boca 
 
Positive 
 
6 (85.7) 
 
57 (68.7) 
 
0.320 
  
 
Fy(a+b-) 
 
6 (85.7) 
 
49 (59.04) 
 
0.163 
  
 
Fy(a-b+) 
 
0 
 
5 (6.02) 
 
0.661 
  
 
Fy(a+b+) 
 
0 
 
3 (3.61) 
 
0.782 
   Negative    Fy(a-b-)   1 (14.3)  26 (31.3)  0.320 
El Guadual 
 
Positive 
 
12 (100) 
 
39 (88.6) 
 
0.284 
  
 
Fy(a+b-) 
 
9 (75.0) 
 
34 (77.27) 
 
0.571 
  
 
Fy(a-b+) 
 
1 (8.33) 
 
1 (2.27) 
 
0.386 
  
 
Fy(a+b+) 
 
2 (16.7) 
 
4 (9.09) 
 
0.381 
   Negative    Fy(a-b-)   0 (0.0)  5 (11.4)  0.284 
Total  
 
Positive 
 
22 (78.6) 
 
202 (69.7) 
 
0.224 
  
 
Fy(a+b-) 
 
18 (64,3) 
 
165 (56,9) 
 
0.292 
  
 
Fy(a-b+) 
 
2 (7,1) 
 
25 (8,6) 
 
0.586 
  
 
Fy(a+b+) 
 
2 (7,1) 
 
12 (4,1) 
 
0.354 
   Negative    Fy(a-b-)   6 (21.4)  88 (30.3)  0.224 
a
P.  falciparum infected and non-infected individuals 
b
P-value was determined by χ2 analysis and the Fisher´s exact test.  
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Table 7. Duffy genotype based on qPCR in P. vivax infected and non-vivax infected 
individuals in four communities of San Lorenzo.  
Place   Duffy genotype   
P. vivax 
infected          
n (%) 
  
Controls
a
            
n (%) 
  p-value
b
         
El Pedregal 
 
FY*A/FY*A 
 
1 (33.3) 
 
19 (33.3) 
 
0.745 
  
 
FY*A/FY*B
ES
 
 
1 (33.3) 
 
12 (21.1) 
 
0.526 
  
 
FY*B/FY*B 
 
0 (0.0) 
 
2 (3.5) 
 
0.902 
  
 
FY*B/FY*B
ES
 
 
0 (0.0) 
 
3 (5.3) 
 
0.855 
  
 
FY*A/FY*B 
 
0 (0.0) 
 
4 (7.0) 
 
0.810 
    FY*B
ES
/FY*B
ES
   1 (33.3)   17 (29.8)   0.665 
Ricaurte 
 
FY*A/FY*A 
 
1 (16.7) 
 
18 (17.0) 
 
0.731 
  
 
FY*A/FY*B
ES
 
 
0 (0.0) 
 
33 (31.1) 
 
0.116 
  
 
FY*B/FY*B 
 
0 (0.0) 
 
4 (3.8) 
 
0.800 
  
 
FY*B/FY*B
ES
 
 
1 (16.7) 
 
10 (9.4) 
 
0.470 
  
 
FY*A/FY*B 
 
0 (0.0) 
 
1 (0.9) 
 
0.946 
    FY*B
ES
/FY*B
ES
   4 (66.7)   40 (37.7)   0.163 
La Boca 
 
FY*A/FY*A 
 
1 (14.3) 
 
10 (12.0) 
 
0.612 
  
 
FY*A/FY*B
ES
 
 
5 (71.4) 
 
39 (47.0) 
 
0.199 
  
 
FY*B/FY*B 
 
0 (0.0) 
 
3  (3.6) 
 
0.782 
  
 
FY*B/FY*B
ES
 
 
0 (0.0) 
 
2 (2.4) 
 
0.850 
  
 
FY*A/FY*B 
 
0 (0.0) 
 
3  (3.6) 
 
0.782 
    FY*B
ES
/FY*B
ES
   1 (14.3)   26 (31.3)   0.320 
El Guadual 
 
FY*A/FY*A 
 
9 (75.0) 
 
21 (47.7) 
 
0.087 
  
 
FY*A/FY*B
ES
 
 
0 (0.0) 
 
13 (29.5) 
 
0.027 
  
 
FY*B/FY*B 
 
0 (0.0) 
 
0 (0.0) 
 
- 
  
 
FY*B/FY*B
ES
 
 
1 (8.3) 
 
1 (2.3) 
 
0.386 
  
 
FY*A/FY*B 
 
2 (16.7) 
 
4 (9.1) 
 
0.381 
    FY*B
ES
/FY*B
ES
   0 (0.0)   5 (11.4)   0.284 
Total  
 
FY*A/FY*A 
 
12 (42,9) 
 
68 (23,5) 
 
0.025 
  
 
FY*A/FY*B
ES
 
 
6 (21,4) 
 
97 (33,5) 
 
0.138 
  
 
FY*B/FY*B 
 
0 (0,0) 
 
9 (3,1) 
 
0.431 
  
 
FY*B/FY*B
ES
 
 
2 (7,1) 
 
16 (5,5) 
 
0.484 
  
 
FY*A/FY*B 
 
2 (7,1) 
 
12 (4,1) 
 
0.354 
    FY*B
ES
/FY*B
ES
   6 (21,4)   88 (30,3)   0.224 
a
P.  falciparum infected and non-infected individuals 
b
P-value was determined by χ2 analysis and the Fisher´s exact test.  
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Table 8. Allele frequencies in P. vivax infected and non-vivax infected individuals in four 
communities of San Lorenzo.  
Place   Alleles   
P. vivax 
infecteded           
(frequency) 
Controls
a
             
(frequency) 
  p-value
b
         
El Pedregal 
 
FY*A 
 
0.500 
 
0.474 
 
0.65 
  
 
FY*B 
 
0 
 
0.096 
 
0.646 
    FY*B
ES
   0.500   0.430   0.601 
Ricaurte 
 
FY*A 
 
0.167 
 
0.330 
 
0.130 
  
 
FY*B 
 
0.083 
 
0.090 
 
0.613 
    FY*B
ES
   0.750   0.580   0.620 
La Boca 
 
FY*A 
 
0.500 
 
0.373 
 
0.214 
  
 
FY*B 
 
0 
 
0.066 
 
0.509 
    FY*B
ES
   0.500   0.560   0.605 
El Guadual 
 
FY*A 
 
0.833 
 
0.670 
 
0.530 
  
 
FY*B 
 
0.125 
 
0.057 
 
0.224 
    FY*B
ES
   0.042   0.273   0.024 
Total  
 
FY*A 
 
0.571 
 
0.422 
 
0.181 
  
 
FY*B 
 
0.071 
 
0.079 
 
0.480 
    FY*B
ES
   0.357   0.498   0.033 
a
P.  falciparum infected and non-infected individuals 
bP-value was determined by χ2 analysis and the Fisher´s exact test.  
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one-line title as well. You may also include a legend in your caption, but it is not required. 
Example caption 
S1 Text. Title is strongly recommended. Legend is optional. 
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requirement. If you cite supporting information in the text, citations do not need to be in 
numerical order. 
Figures and tables 
Figures 
Do not include figures in the main manuscript file. Each figure must be prepared and 
submitted as an individual file. 
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Figure captions 
Figure captions must be inserted in the text of the manuscript, immediately following the 
paragraph in which the figure is first cited (read order). Do not include captions as part of 
the figure files themselves or submit them in a separate document. 
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Data reporting 
All data and related metadata underlying the findings reported in a submitted manuscript 
should be deposited in an appropriate public repository, unless already provided as part of 
the submitted article. 
Repositories may be either subject-specific (where these exist) and accept specific types of 
structured data, or generalist repositories that accept multiple data types. We recommend 
that authors select repositories appropriate to their field. Repositories may be subject-
specific (e.g., GenBank for sequences and PDB for structures), general, or institutional, as 
long as DOIs or accession numbers are provided and the data are at least as open as CC 
BY. Authors are encouraged to select repositories that meet accepted criteria as 
trustworthy digital repositories, such as criteria of the Centre for Research Libraries or 
Data Seal of Approval. Large, international databases are more likely to persist than small, 
local ones. 
To support data sharing and author compliance of the PLOS data policy, we have 
integrated our submission process with a select set of data repositories. The list is neither 
representative nor exhaustive of the suitable repositories available to authors. Current 
repository integration partners include Dryad and FlowRepository. Please contact 
data@plos.org to make recommendations for further partnerships. 
Instructions for PLOS submissions with data deposited in an integration partner repository: 
 Deposit data in the integrated repository of choice. 
 Once deposition is final and complete, the repository will provide you with a 
dataset DOI (provisional) and private URL for reviewers to gain access to the data. 
 Enter the given data DOI into the full Data Availability Statement, which is 
requested in the Additional Information section of the PLOS submission form. 
Then provide the URL passcode in the Attach Files section. 
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If you have any questions, please email us. 
Accession numbers 
All appropriate data sets, images, and information should be deposited in an appropriate 
public repository. See our list of recommended repositories. 
Accession numbers (and version numbers, if appropriate) should be provided in the Data 
Availability Statement. Accession numbers or a citation to the DOI should also be 
provided when the data set is mentioned within the manuscript. 
In some cases authors may not be able to obtain accession numbers of DOIs until the 
manuscript is accepted; in these cases, the authors must provide these numbers at 
acceptance. In all other cases, these numbers must be provided at submission. 
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 Online Mendelian Inheritance in Man (OMIM) 
 PubChem 
Identifiers should be provided in parentheses after the entity on first use. 
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You can choose to upload a “Striking Image” that we may use to represent your article 
online in places such as the journal homepage. All striking image files that are submitted 
are also eligible to be chosen as the monthly Isuse Image. 
The striking image must visually represent the article in a striking and eye-catching way. 
This could be derived from a figure or supporting information file from the paper, i.e., a 
cropped portion of an image or the entire image. Alternatively, you may create or source 
an image which represents the article, as long as this image adheres to our CC BY license. 
Striking images should ideally be high resolution, eye-catching, single panel images, and 
should ideally avoid containing added details such as text, scale bars, and arrows. 
If no striking image is uploaded, a member of the journal team will choose an appropriate 
image, which may be a figure from the submission or a separately sourced CC BY image. 
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submitted a similar manuscript for publication elsewhere. If related work has been 
submitted elsewhere, then a copy must be included with the manuscript submitted to 
PLOS. Reviewers will be asked to comment on the overlap between related submissions. 
Guidelines for Specific Study Types 
Human and animal research 
All research involving humans and animals must have been approved by the authors' 
institutional review board or equivalent committee(s), and that board must be named by the 
authors in the manuscript. For research involving human participants, informed consent 
must have been obtained (or the reason for lack of consent explained, e.g. the data were 
analyzed anonymously) and all clinical investigation must have been conducted according 
to the principles expressed in the Declaration of Helsinki. It must be stated in the Methods 
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oral, it must be stated in the paper: (a) why written consent could not be obtained, (b) that 
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primates. The institution that approved the study must be named, and it must be stated in 
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the paper that the study was conducted adhering to the institution's guidelines for animal 
husbandry. 
Patient privacy and informed consent for publication  
Our human participant policy conforms to the Uniform Requirements of the International 
Committee of Medical Journal Editors:  
Patients have a right to privacy that should not be infringed without informed consent. 
Identifying information should not be published in written descriptions, photographs, and 
pedigrees unless the information is essential for scientific purposes and the patient (or 
parent or guardian) gives written informed consent for publication. Informed consent for 
this purpose requires that the patient be shown the manuscript to be published. Complete 
anonymity is difficult to achieve, and informed consent for publication should be obtained 
if there is any doubt. If data are changed to protect anonymity, authors should provide 
assurance that alterations of the data do not distort scientific meaning. When informed 
consent has been obtained it should be indicated in the published article.  
For papers that include identifying information, or potentially identifying information, 
authors must download the  Consent Form for Publication in a PLOS Journal from our 
web site, which the patient, parent, or guardian must sign once they have read the paper 
and been informed about the terms of the PLOS content license.   
Once authors have obtained the signed consent form, it should be filed securely in the 
patient's case notes and the manuscript submitted to PLOS should include this statement 
indicating that specific consent for publication was obtained: “The patients in this 
manuscript have given written informed consent (as outlined in the PLOS consent form) to 
publication of their case details.”  
Clinical trials 
We follow the World Health Organization’s (WHO) definition of a clinical trial: 
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A clinical trial is any research study that prospectively assigns human participants or 
groups of humans to one or more health-related interventions to evaluate the effects on 
health outcomes [...] Interventions include but are not restricted to drugs, cells and other 
biological products, surgical procedures, radiologic procedures, devices, behavioural 
treatments, process-of-care changes, preventive care, etc. 
PLOS Neglected Tropical Diseases requires that all trials be registered and, as of August 
13, 2013, supports the position of the AllTrials.net Initiative that trials that are registered 
after the trial commences or retrospectively will be considered (see the blog post for more 
details). For all trials, authors are asked to provide the trial registration information and to 
register their trial in an approved registry (the WHO's list of approved registries is listed 
here). For trials that were registered after the trial began or retrospectively, authors are 
asked to provide the following information: 
 The trial registration information (or indicate that registration is in process) 
 The reason for late registration, explained within the Methods section 
 A statement in which all authors affirm that any trials on the same or a related drug 
or intervention they're involved in are registered, and provide (either as part of the 
statement or in the supplementary information) links to the published versions of 
the trials or the registration numbers. This statement will be published in the 
Methods section. 
The editors reserve the right to inform authors' institutions or ethics committees about 
unregistered trials that have been carried out. Authors will also be asked to submit an 
accurate summary of the trial's results to the relevant registry (if there is such a 
mechanism) within a year of study completion or at the time of publication, whichever is 
the earliest. 
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Authors of trials must adhere to the CONSORT reporting guidelines appropriate to their 
trial design. Please check the CONSORT statement web site for information on the 
appropriate guidelines for specific trial types. Before the paper can undergo peer review, 
authors must: 1) provide in the manuscript the trial registry, trial registration number, and 
IRB, and 2) provide a copy of the trial protocol (or a link to an open access version of the 
protocol) and a completed CONSORT checklist as supporting files (these documents will 
also be published alongside the paper, if accepted). The CONSORT flow diagram must be 
included as Figure 1. Any deviation from the trial protocol must be explained in the paper. 
Authors must explicitly discuss informed consent in their paper, and PLOS reserves the 
right to request a copy of the patient consent form. Information on statistical methods or 
participants beyond what is indicated in the CONSORT statement should be reported in the 
Methods section. 
PLOS supports the public disclosure of all clinical trial results, as mandated, for example, 
by the FDA Amendments Act, 2007. For trials in registries that permit posting of trial 
results, PLOS Neglected Tropical Diseases requires that an accurate summary of the trial's 
results be submitted to the relevant registry (if there is such a mechanism) within a year of 
study completion or at the time of publication, whichever is the earliest. 
Systematic reviews and meta-analyses 
Reports of systematic reviews and meta-analyses must adhere to the PRISMA Statement or 
alternative guidelines appropriate to the study design, and include the completed checklist 
and flow diagram to accompany the main text. Authors must complete the appropriate 
reporting checklist not only with page references, but also with sufficient text excerpted 
from the manuscript to explain how they accomplished all applicable items. 
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Abstracts should follow PRISMA for Abstracts, using the PLOS abstract format. Authors 
must also state within the Methods section of their paper whether a protocol exists for their 
systematic review, and if so, provide a copy of the protocol as supporting information. 
The journal supports the prospective registration of systematic reviews. Authors whose 
systematic review was prospectively registered (e.g., in a registry such as PROSPERO) 
should provide the registry number in their abstract. Registry details and protocols will be 
made available to editors and reviewers, and included with the paper if the report is 
ultimately published. 
Diagnostic studies 
Reports of studies of diagnostic accuracy must adhere to the STARD requirements or 
alternative guidelines appropriate to the study design (see the EQUATOR web site) and 
include a completed checklist as supporting information. Authors must complete the 
appropriate reporting checklist not only with page references, but also with sufficient text 
excerpted from the manuscript to explain how they addressed all applicable items. 
Observational studies 
For observational studies, including case control, cohort, and cross-sectional studies, 
authors must adhere to the STROBE Statement or alternative guidelines appropriate to the 
study design (see the EQUATOR web site) and include a completed checklist as 
supporting information. Authors must complete the appropriate reporting checklist not 
only with page references, but also with sufficient text excerpted from the manuscript to 
explain how they addressed all applicable items. 
For observational studies, authors are required to clearly specify (a) What specific 
hypotheses the researchers intended to test, and the analytical methods by which they 
planned to test them; (b) What analyses they actually performed; and (c) When reported 
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analyses differ from those that were planned, authors must provide transparent 
explanations for differences that affect the reliability of the study's results. 
If a prospective analysis plan (from the study's funding proposal, IRB or other ethics 
committee submission, study protocol, or other planning document written before 
analyzing the data) was used in designing an observational study, authors must include the 
relevant prospectively written document with the manuscript submission for access by 
editors and reviewers and eventual publication alongside the accepted paper. If no 
prospectively written document exists, authors should explain how and when they 
determined the analyses being reported. 
Microarray experiments 
Reports of microarray experiments must conform to the MIAME guidelines, and the data 
from the experiments must be deposited in a publicly accessible database. 
Other Article Types 
If you are submitting content other than a research article, read the guidelines for other 
article types. 
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